U-M Tech Transfer's Impact . . .
Cerdelga, licensed by the University of Michigan to Genzyme Corporation, promises to be a landmark therapy for patients worldwide afflicted with Gaucher disease, thanks to the work of our researchers and the significant investment of time, expertise, and resources by Genzyme.
Printed from: http://techtransfer.umich.edu/index.php